(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/014371 A1

(51) International Patent Classification[7]: A61K 31/425, C07D 277/82, 493/04, 417/12, A61P 31/18

(21) International Application Number: PCT/EP2003/050359

(22) International Filing Date: 4 August 2003 (04.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02078231.4 2 August 2002 (02.08.2002) EP
60/427,862 20 November 2002 (20.11.2002) US

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Unit 4, Block 4B, Blanchardstown Corporate Park, Blanchardstown 15, Dublin (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SURLERAUX, Dominique, Louis, Nestor, Ghislain** [BE/BE]; Diegemstraat 48, B-1830 Machelen (BE). **WIGERINCK, Piet, Tom, Bert, Paul** [BE/BE]; Kardinaal Cardijnstraat 29, B-2840 Terhagen (BE). **GETMAN, Daniel, P.** [US/US]; 66 Sunnyhill Court, Chesterfield, MO 63017 (US).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L11 B3, B-2800 Mechelen (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv)) for US only*

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/014371 A1

(54) Title: BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS



(I)

(57) Abstract: The present invention relates to the use of 2-amino-benzothiazoles, having the formula (I) wherein R_1 is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C_{1-6}-alkyl, hydroxy, amino, halogen, aminoC_{1-4}-alkyl and mono-or di(C_{1-4}alkyl)amino; R_2 is hydrogen or C_{1-6}alkyl; L is a direct bond, -0-, C_{1-6}alkanediyl-O- or -O-C_{1-6}alkanediyl; R_3 is phenylC_{1-4}alkyl; R_4 is C_{1-6}alkyl; R_5 is hydrogen or C_{1-6}alkyl; R_6 is hydrogen or C_{1-6}alkyl; in the manufacture of a medicament useful for inhibiting mutant HIV protease in a mammal infected with said mutant HIV protease. It also relates to novel compounds of formula (I).